Biological Products, (No Diagnostic Substances) · DE · CIK 1650664
Editas Medicine develops genomic medicines using CRISPR gene editing to treat serious diseases
Comparable business profile · signals at a glance
In the 90 days to Mar 3, 2026: 3 sold $28K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 3, 2026 | O'Neill Gilmore NeilCEO | Sell | 5,394 | $2.02 | $11K |
| Mar 3, 2026 | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Sell | 749 | $2.02 | $2K |
| Mar 3, 2026 | Parison AmySVP, Chief Financial Officer | Sell | 474 | $2.02 | $957 |
| Dec 3, 2025 | O'Neill Gilmore NeilCEO | Sell | 5,603 | $2.15 | $12K |
| Dec 3, 2025 | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Sell | 713 | $2.15 | $2K |
| Dec 3, 2025 | Parison AmySVP, Chief Financial Officer | Sell | 461 | $2.15 | $991 |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.